Genetic variants of the renin-angiotensin-aldosterone system and reverse remodeling after cardiac resynchronization therapy

Journal of Cardiac Failure

Volumn 18, Issue 10, 2012, Pages 762-768

  De Maria, Renata ^a   Landolina, Maurizio ^b   Gasparini, Maurizio ^c   Schmitz, Boris ^d   Campolo, Jonica ^a   Parolini, Marina ^a   Sanzo, Antonio ^b   Galimberti, Paola ^c   Bianchi, Michele ^a   Brand, Stefan Martin ^d,e   Parodi, Oberdan ^a   Lunati, Maurizio ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e Leibniz Institute for Arteriosclerosis Research   (Germany)

Author keywords

cardiac resynchronization therapy; Heart failure; mineralocorticoid receptor; NR3C2; reverse remodeling

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE REMODELING;

AGED; CARDIAC RESYNCHRONIZATION THERAPY; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; GENETIC VARIATION; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; PILOT PROJECTS; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; STATISTICS AS TOPIC; VENTRICULAR REMODELING;

EID: 84867193858     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2012.07.008     Document Type: Article

References (33)

1. M.R. Bristow, L.A. Saxon, J. Boehmer, S. Krueger, D.A. Kass, T. de Marco Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators Cardiac resynchronization therapy with or without an implantable defibrillator in advanced heart failure N Eng J Med 350 2004 2140 2150
2. J.G. Cleland, J.C. Daubert, E. Erdmann, N. Freemantle, D. Gras, L. Kappenberger Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators The effect of cardiac resynchronization on morbidity and mortality in heart failure N Engl J Med 352 2005 1539 1549
3. M.G. St John Sutton, T. Plappert, W.T. Abraham, A.L. Smith, D.B. DeLurgio, A.R. Leon Multicenter In-Sync Randomized Clinical Evaluation (MIRACLE) Study Group Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure Circulation 107 2003 1985 1990
4. D. Verhaert, R.A. Grimm, C. Puntawangkoon, K. Wolski, S. De, B.L. Wilkoff, and R.C. Starling Long-term reverse remodeling with cardiac resynchronization therapy. Results of extended echocardiographic follow-up J Am Coll Cardiol 55 2010 1788 1795
5. S. Ghio, N. Freemantle, L. Scelsi, A. Serio, G. Magrini, and M. Pasotti Long-term left ventricular reverse remodeling with cardiac resynchronization therapy: results from the CARE-HF trial Eur J Heart Fail 11 2009 480 488
6. C. Ypenburg, R.J. van Bommel, C.J. Borleffs, G.B. Bleeker, E. Boersma, and M.J. Schalij Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up J Am Coll Cardiol 53 2009 483 490
7. C.M. Yu, G.B. Bleeker, J.W. Fung, M.J. Schalij, Q. Zhang, and E.E. van der Wall Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy Circulation 112 2005 1580 1586
8. P.W. Foley, S. Chalil, K. Khadjooi, N. Irwin, R.E. Smith, and F. Leyva Left ventricular reverse remodeling, long-term clinical outcome, and mode of death after cardiac resynchronization therapy Eur J Heart Fail 13 2011 43 51
9. R.J. van Bommel, J.J. Bax, W.T. Abraham, E.S. Chung, L.A. Pires, and L. Tavazzi Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis Eur Heart J 30 2009 2470 2477
10. B. Vidal, V. Delgado, L. Mont, S. Poyatos, E. Silva, and M. Angeles Castel Decreased likelihood of response to cardiac resynchronization in patients with severe heart failure Eur J Heart Fail 12 2010 283 287
11. G. Wikstrom, C. Blomström-Lundqvist, B. Andren, S. Lönnerholm, P. Blomström, N. Freemantle CARE-HF Study Investigators The effects of etiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial Eur Heart J 30 2009 782 788
12. M. Gasparini, A. Auricchio, F. Regoli, C. Fantoni, M. Kawabata, and P. Galimberti Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression. The importance of performing atrioventricular junction ablation in patients with atrial fibrillation J Am Coll Cardiol 48 2006 734 743
13. A. Arshad, A.J. Moss, E. Foster, L. Padeletti, A. Barsheshet, I. Goldenberg MADIT-CRT Executive Committee Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial J Am Coll Cardiol 57 2011 813 820
14. Gasparini M, F, Ceriotti C, Galimberti P, Bragato R, de Vita S, Pini D, et al. Remission of left ventricular systolic dysfunction and of heart failure symptoms after cardiac resynchronization therapy: temporal pattern and clinical predictors. Am Heart J 2008;155:507-14.
15. C. Linde, W.T. Abraham, M.R. Gold, C. Daubert REVERSE Study Group Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) study J Am Coll Cardiol 56 2010 1826 1831
16. G.S. Bleumink, A.F. Schut, M.C. Sturkenboom, J.W. Deckers, C.M. van Duijn, and B.H. Stricker Genetic polymorphisms and heart failure Genet Med 6 2004 465 474
17. C.A. MacRae The genetics of congestive heart failure Heart Fail Clin 6 2010 223 230
18. K. Dickstein, P.E. Vardas, A. Auricchio, J.C. Daubert, C. Linde, and J. McMurray 2010 Focused update of ESC guidelines on device therapy in heart failure Eur Heart J 31 2010 2677 2687
19. X. Zhu, N. Bouzekri, L. Southam, R.S. Cooper, A. Adeyemo, and C.A. McKenzie Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure Am J Hum Genet 68 2001 1139 1148
20. Y. Benjamini, and D. Yekutieli The control of the false discovery rate in multiple testing under dependency Ann Stat 29 2001 1165 1188
21. D. Auger, R.J. van Bommel, M. Bertini, V. Delgado, A.C. Ng, and S.H. Ewe Prevalence and characteristics of patients with clinical improvement but not significant left ventricular reverse remodeling after cardiac resynchronization therapy Am Heart J 160 2010 737 743
22. B.K. Fornwalt, W.W. Sprague, P. BeDell, J.D. Suever, B. Gerritse, and J.D. Merlino Agreement is poor among current criteria used to define response to cardiac resynchronization therapy Circulation 121 2010 1985 1991
23. D.A. Kass Pathobiology of cardiac dyssynchrony and resynchronization Heart Rhythm 6 2009 1660 1665
24. D.T. Martin, S. McNitt, R.W. Nesto, M.K. Rutter, and A.J. Moss Cardiac resynchronization therapy reduces the risk of cardiac events in patients with diabetes enrolled in the MADIT-CRT Trial Circ Heart Fail 4 2011 332 338
25. C. Fantoni, F. Regoli, A. Ghanem, S. Raffa, C. Klersy, and A. Sorgente Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy Eur J Heart Fail 10 2008 298 307
26. J.M. Connell, S.M. MacKenzie, E.M. Freel, R. Fraser, and E. Davies A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function Endocr Rev 29 2008 133 154
27. J.W. Funder Aldosterone and mineralocorticoid receptors in the cardiovascular system Prog Cardiovasc Dis 52 2010 393 400
28. S. Messaoudi, F. Azibani, C. Delcayre, and F. Jaisser Aldosterone, mineralocorticoid receptor, and heart failure Mol Cell Endocrinol 350 2012 266 272
29. Galuppo P, Bauersachs J. Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances. Eur J Clin Invest. Epub ahead of print 2012 March 28. http://dx.doi.org/10.1111/j.1365-2362.2012.02676. x.
30. D. Fraccarollo, S. Berger, P. Galuppo, S. Kneitz, L. Hein, and G. Schütz Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction Circulation 123 2011 400 408
31. S. Kathiresan, M.G. Larson, E.J. Benjamin, D. Corey, J.M. Murabito, and C.S. Fox Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study Am J Hypertens 18 2005 657 665
32. A.S. Bomback, and P.J. Klemmer The incidence and implications of aldosterone breakthrough Nat Clin Pract Nephrol 3 2007 486 492
33. J.I. Koontz, D. Haithcock, V. Cumbea, A. Waldron, K. Stricker, and A. Hughes Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository Am Heart J 158 2009 719 725